Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications.

PubWeight™: 4.90‹?› | Rank: Top 1%

🔗 View Article (PMC 2903869)

Published in Transplant Proc on February 01, 1990

Authors

J J Fung1, S Todo, A Jain, J McCauley, M Alessiani, C Scotti, T E Starzl

Author Affiliations

1: Department of Surgery, University of Pittsburgh School of Medicine, PA.

Articles citing this

Kidney transplantation under FK 506. JAMA (1990) 7.45

Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01

Kidney transplantation under FK 506 immunosuppression. Transplant Proc (1991) 3.31

The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14

Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg (2000) 2.91

Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. Transplant Proc (1991) 2.59

FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation (1994) 2.50

A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. Transplant Proc (1991) 2.49

Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. Transplant Proc (1991) 2.26

Randomised trialomania? The multicentre liver transplant trials of tacrolimus. Lancet (1995) 2.04

Use of FK 506 in pediatric patients. Transplant Proc (1991) 1.77

The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation. J Am Coll Surg (1996) 1.71

Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy--a clinicopathologic study of 96 patients. Transplantation (1992) 1.45

Adverse effects associated with the use of FK 506. Transplant Proc (1991) 1.41

A clinical trial of FK 506 as primary and rescue immunosuppression in cardiac transplantation. Transplant Proc (1991) 1.40

FK 506 conversion of renal allografts failing cyclosporine immunosuppression. Transplant Proc (1991) 1.37

Tacrolimus (FK 506)--a new therapeutic agent for severe recalcitrant psoriasis. Arch Dermatol (1992) 1.32

Clinical trial of FK 506 immunosuppression in adult cardiac transplantation. Ann Thorac Surg (1992) 1.18

The clinical trial of FK 506 as primary and rescue immunosuppression in adult cardiac transplantation. Transplant Proc (1991) 1.16

Current status of FK 506 in liver transplantation. Transplant Proc (1991) 1.04

What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients. Ann Surg (1999) 1.02

Histopathology of human renal allograft rejection under FK 506: a comparison with cyclosporine. Transplant Proc (1991) 1.02

FK 506 in the management of transplant-related nephrotic syndrome and steroid-resistant nephrotic syndrome. Transplant Proc (1991) 1.00

Preliminary experience with FK506 in thoracic transplantation. Transplantation (1991) 0.97

Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 years. Liver Transpl (2001) 0.93

Comparative long-term evaluation of tacrolimus and cyclosporine in pediatric liver transplantation. Transplantation (2000) 0.92

History of clinical transplantation. World J Surg (2000) 0.91

Tacrolimus (FK506)-Associated Renal Pathology. Adv Anat Pathol (1997) 0.90

Changes in renal function after liver transplantation under FK 506. Transplant Proc (1991) 0.88

Liver transplantation of American veterans under FK 506 immunosuppression: a preliminary report. Transplant Proc (1991) 0.87

FK506 in solid organ transplantation. Ther Drug Monit (1995) 0.85

Recent advances in hepatic transplantation at the University of Pittsburgh. Clin Transpl (1993) 0.83

Primary adult liver transplantation under tacrolimus: more than 90 months actual follow-up survival and adverse events. Liver Transpl Surg (1999) 0.81

FK 506 used as rescue therapy for human liver allograft recipients. Transplant Proc (1991) 0.80

FK 506 prevents spontaneous diabetes in the BB rat. Transplant Proc (1991) 0.80

Liver transplantation: history, outcomes and perspectives. Einstein (Sao Paulo) (2015) 0.79

The current status of hepatic transplantation at the University of Pittsburgh. Clin Transpl (1995) 0.76

Overview of FK506 in transplantation. Clin Transpl (1990) 0.76

Renal function after conversion from cyclosporine to FK 506 in liver transplant patients. Transplant Proc (1991) 0.76

Hepatic transplantation at the University of Pittsburgh: new horizons and paradigms after 30 years of experience. Clin Transpl (1994) 0.76

In-vitro interaction of a novel immunosuppressant, FK 506, and antacids. J Pharm Pharmacol (1991) 0.75

Tacrolimus (FK506) and the pharmaceutical/academic/regulatory gauntlet. Am J Kidney Dis (1998) 0.75

The mother lode of liver transplantation, with particular reference to our new journal. Liver Transpl Surg (1998) 0.75

Effect of renal ischemia on plasma levels of FK 506 in rats. Transplant Proc (1992) 0.75

Articles cited by this

FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70

Effect of a new immunosuppressive agent, FK 506, on heterotopic cardiac allotransplantation in the rat. Transplant Proc (1987) 12.04

FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo) (1987) 7.07

Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction. Surgery (1988) 5.03

Liver transplantation (1). N Engl J Med (1989) 4.53

Heterotopic heart transplantation in the rat receiving FK-506 alone or with cyclosporine. Transplant Proc (1987) 4.21

Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A. Transplant Proc (1987) 3.73

Canine kidney transplantation with FK-506 alone or in combination with cyclosporine and steroids. Transplant Proc (1987) 3.55

IN VITRO IMMUNOSUPPRESSIVE EFFECTS OF FR 900506 ON HUMAN T LYMPHOCYTE ALLOACTIVATION. Surg Res Commun (1987) 3.46

Renal transplantation in baboons under FK 506. Surgery (1989) 3.17

Orthotopic liver transplantation in dogs receiving FK-506. Transplant Proc (1987) 3.11

Discovery of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. Transplant Proc (1987) 2.30

Studies of the induction and maintenance of long-term graft acceptance by treatment with FK506 in heterotopic cardiac allotransplantation in rats. Transplantation (1987) 2.15

Studies of the effects of FK506 on renal allografting in the beagle dog. Transplantation (1987) 1.65

Kidney transplantation in the dog receiving FK-506. Transplant Proc (1987) 1.54

The effect of FK-506 on hyperacute rejection in presensitized rats. Transplant Proc (1987) 1.49

Observations about FK-506 in primates. Transplant Proc (1987) 1.25

Synthesis and structure-activity relationships of C-4-amino acid substituted monobactam analogs. J Antibiot (Tokyo) (1987) 0.96

Articles by these authors

Evolution of liver transplantation. Hepatology (1982) 19.54

FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70

A flexible procedure for multiple cadaveric organ procurement. Surg Gynecol Obstet (1984) 10.33

Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76

Orthotopic liver transplantation in ninety-three patients. Surg Gynecol Obstet (1976) 8.11

Kidney transplantation under FK 506. JAMA (1990) 7.45

The use of cyclosporin A and prednisone in cadaver kidney transplantation. Surg Gynecol Obstet (1980) 7.40

The use of heterologous antilymphoid agents in canine renal and liver homotransplantation and in human renal homotransplantation. Surg Gynecol Obstet (1967) 7.24

Fifteen years of clinical liver transplantation. Gastroenterology (1979) 7.19

Venous bypass in clinical liver transplantation. Ann Surg (1984) 7.04

Liver transplantation with use of cyclosporin a and prednisone. N Engl J Med (1981) 6.95

The many faces of multivisceral transplantation. Surg Gynecol Obstet (1991) 6.89

Orthotopic homotransplantation of the human liver. Ann Surg (1968) 6.64

Vascular homografts from cadaveric organ donors. Surg Gynecol Obstet (1979) 6.23

Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92

Abdominal organ cluster transplantation for the treatment of upper abdominal malignancies. Ann Surg (1989) 5.78

Infections after liver transplantation. An analysis of 101 consecutive cases. Medicine (Baltimore) (1988) 5.77

Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet (1984) 5.74

Refinements in the surgical technique of liver transplantation. Semin Liver Dis (1985) 5.70

Progress in and deterrents to orthotopic liver transplantation, with special reference to survival, resistance to hyperacute rejection, and biliary duct reconstruction. Transplant Proc (1974) 5.53

Extended survival in 3 cases of orthotopic homotransplantation of the human liver. Surgery (1968) 5.44

Cyclophosphamide and whole organ transplantation in human beings. Surg Gynecol Obstet (1971) 5.24

Alternative methods of arterialization of the hepatic graft. Surg Gynecol Obstet (1984) 5.16

Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction. Surgery (1988) 5.03

Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01

Pancreaticoduodenal transplantation in humans. Surg Gynecol Obstet (1984) 4.49

Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32

A simplified technique for revascularization of homografts of the liver with a variant right hepatic artery from the superior mesenteric artery. Surg Gynecol Obstet (1985) 4.29

Heterotopic heart transplantation in the rat receiving FK-506 alone or with cyclosporine. Transplant Proc (1987) 4.21

Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18

Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery (1994) 4.16

Orthotopic liver transplantation with preservation of the inferior vena cava. Ann Surg (1989) 4.12

Malignant lymphomas in transplantation patients. Transplant Proc (1969) 4.12

Role of liver transplantation in cancer therapy. Ann Surg (1985) 4.08

Biliary complications after liver transplantation: with special reference to the biliary cast syndrome and techniques of secondary duct repair. Surgery (1977) 4.08

Shwartzman reaction after human renal homotransplantation. N Engl J Med (1968) 4.05

Baboon-to-human liver transplantation. Lancet (1993) 4.01

Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med (2001) 4.01

Extended preservation of human liver grafts with UW solution. JAMA (1989) 3.99

Canine and human liver preservation for 6 to 18 hr by cold infusion. Transplantation (1977) 3.99

Clinical presentation of hepatic artery thrombosis after liver transplantation in the cyclosporine era. Transplantation (1985) 3.91

The preparation and testing of horse antidog and antihuman antilymphoid plasma or serum and its protein fractions. Surg Gynecol Obstet (1967) 3.86

Replacement of donor lymphoid tissue in small-bowel transplants. Lancet (1991) 3.85

The origin, hormonal nature, and action of hepatotrophic substances in portal venous blood. Surg Gynecol Obstet (1973) 3.84

Effects of insulin, glucagon, and insuling/glucagon infusions on liver morphology and cell division after complete portacaval shunt in dogs. Lancet (1976) 3.74

Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A. Transplant Proc (1987) 3.73

Hepatic trisegmentectomy and other liver resections. Surg Gynecol Obstet (1975) 3.66

Right trisegmentectomy for hepatic neoplasms. Surg Gynecol Obstet (1980) 3.64

Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation (1995) 3.63

Hepatic Retransplantation. Transplant Proc (1985) 3.62

Transplantation of multiple abdominal viscera. JAMA (1989) 3.59

Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg (1991) 3.57

Canine liver transplantation under Nva2-cyclosporine versus cyclosporine. Transplantation (1986) 3.54

Implementation of a high-sensitivity Micro-Angiographic Fluoroscope (HS-MAF) for in-vivo endovascular image guided interventions (EIGI) and region-of-interest computed tomography (ROI-CT). Proc SPIE Int Soc Opt Eng (2008) 3.49

Combination donor hepatectomy and nephrectomy and early functional results of allografts. Surg Gynecol Obstet (1982) 3.49

Long-term survival after renal transplantation in humans: (with special reference to histocompatibility matching, thymectomy, homograft glomerulonephritis, heterologous ALG , AND RECIPIENT MALIGNANCY). Ann Surg (1970) 3.48

IN VITRO IMMUNOSUPPRESSIVE EFFECTS OF FR 900506 ON HUMAN T LYMPHOCYTE ALLOACTIVATION. Surg Res Commun (1987) 3.46

Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc (1991) 3.40

Nephrotoxicity of cyclosporin A in liver and kidney transplant patients. Lancet (1981) 3.38

The relation of preoperative coagulation findings to diagnosis, blood usage, and survival in adult liver transplantation. Transplantation (1985) 3.38

Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34

Kidney transplantation under FK 506 immunosuppression. Transplant Proc (1991) 3.31

Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29

Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26

Delayed biliary duct obstruction after orthotopic liver transplantation. Surgery (1972) 3.26

The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol (1988) 3.24

Changes in blood coagulation. Arch Surg (1966) 3.22

Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18

Renal transplantation in baboons under FK 506. Surgery (1989) 3.17

Intraoperative changes in blood coagulation and thrombelastographic monitoring in liver transplantation. Anesth Analg (1985) 3.17

Pathology of hepatic transplantation: A review of 62 adult allograft recipients immunosuppressed with a cyclosporine/steroid regimen. Am J Pathol (1985) 3.16

Liver transplantation before 1 year of age. J Pediatr (1987) 3.15

In Vitro Immunosuppressive Effects of FK506 in Combination With Other Drugs. Transplant Proc (1988) 3.15

The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14